Get the Stockscreener App
83.58
0.05%
-0.04
After Hours:
83.57
-0.01
-0.01%
Crinetics Pharmaceuticals Inc stock is traded at $83.58, with a volume of 7.36M.
It is down -0.05% in the last 24 hours and up +143.53% over the past month.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
See More
Previous Close:
$83.62
Open:
$83.61
24h Volume:
7.36M
Relative Volume:
2.48
Market Cap:
$8.85B
Revenue:
$18.07M
Net Income/Loss:
$-496.39M
P/E Ratio:
-16.28
EPS:
-5.1333
Net Cash Flow:
$-419.52M
1W Performance:
+97.92%
1M Performance:
+143.53%
6M Performance:
+56.96%
1Y Performance:
+161.27%
1-Day Range:
$83.58
$83.76
1-Week Range:
$41.39
$83.76
52-Week Range:
$25.83
$83.76
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
83.58 | 8.85B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals Announces Merger Agreement With Vertex - TipRanks
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal - Stock Titan
Why This Pharmaceutical Stock Jumped Close to 100% This Week - Yahoo Finance
Why This Pharmaceutical Stock Jumped Close to 100% This Week - The Motley Fool
Price to book forward of Crinetics Pharmaceuticals Inc – DUS:6Z4 - TradingView
Crinetics Pharmaceuticals (CRNX) to be Acquired by Vertex Pharma - GuruFocus
Why Crinetics Stock Soared 99% This Week - 24/7 Wall St.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) - PR Newswire
CNBC ‘Final Trades’: Nvidia, Vertex Pharmaceuticals And More OnRoundhill Memory ETF (BATS:DRAM) - Benzinga
Why Is Crinetics (NASDAQ:CRNX) Expanding Rare Disease Focus? - Kalkine Media
Vertex’s $10 Billion Crinetics Acquisition Lands Amid Record Stock High: Time to Buy? - NAI500
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled - TradingKey
Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Crinetics Pharmaceuticals Shares Surged This Week - AskTraders
CRINETICS PHARMACEUTICALS, INC. (CRNX) - MSN
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex - Wilson Sonsini
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - Business Wire
Vertex’s Crinetics Deal Balances Growth with Integration Risk - MarketBeat
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback? - Yahoo Finance
PR News | Joele Frank Works Crinetics' $8.8B DealWed., Jul. 8, 2026 - O'Dwyer's PR
Stifel cuts Crinetics stock rating to hold on Vertex acquisition - Investing.com
American Vertex Pharmaceuticals acquires Crinetics for $10 billion - AKM.RU
Morgan Stanley Analyzes Vertex Pharmaceuticals' (VRTX.US) $10 Billion Acquisition of Crinetics: Completing Its Endocrinology Pipeline and Unlocking Growth Potential with Two Core Drugs - 富途牛牛
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now? - Yahoo Finance
Vertex to acquire Crinetics in deal worth around $10.0bn - PMLiVE
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil - BioSpace
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - The Motley Fool
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength? - Yahoo Finance
The $10B Integration Problem Vertex Hasn’t Solved Yet - The Clinical Trial Vanguard
Narrow-Moat Vertex's Strong CF Cash Flows Support Expansion Into Endocrinology Via Crinetics - Morningstar
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. - The Motley Fool
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout - Yahoo Finance
Vertex Drops $10 Billion in Record Deal for Rare-Disease Specialist Crinetics - finance.biggo.com
Big week for M&A brings three rare disease takeouts: Deals Report - biocentury.com
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $10 Billion All-Cash Deal - Global Legal Chronicle
Vertex to acquire Crinetics in $10 billion rare-disease push - MSN
Investigation launched into Crinetics Pharma bo... - Pluang
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms - The Boston Globe
Vertex to Acquire Crinetics in $10 Billion Merger - The Globe and Mail
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals director sells $120,000 in stock - Investing.com
Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal - MedCity News
Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout - Genetic Engineering and Biotechnology News
Crinetics Pharmaceuticals director sells $120,000 in stock By Investing.com - Investing.com Canada
Crinetics (CRNX) director sells 3,000 shares at $40 in planned trade - Stock Titan
Vertex further diversifies with ‘fifth pillar’ via $10B Crinetics acquisition - biocentury.com
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology - Yahoo Finance
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles - Investor's Business Daily
Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit - Yahoo Finance
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):